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Inﬂammatory Inﬁltrate in Rosacea Reveals Activation
of Th1/Th17 Pathways
Timo Buhl1,2,3,7, Mathias Sulk3,4,7, Pawel Nowak4,7, Jörg Buddenkotte4, Ian McDonald2, Jérôme Aubert5,
Isabelle Carlavan5, Sophie Déret5, Pascale Reiniche5, Michel Rivier5, Johannes J. Voegel5 and
Martin Steinhoff2,3,6
Rosacea is a common chronic inﬂammatory skin disease of unknown etiology. Our knowledge about an
involvement of the adaptive immune system is very limited. We performed detailed transcriptome analysis,
quantitative real-time reverse-transcriptase–PCR, and quantitative immunohistochemistry on facial biopsies of
rosacea patients, classiﬁed according to their clinical subtype. As controls, we used samples from patients with
facial lupus erythematosus and healthy controls. Our study shows signiﬁcant activation of the immune system in
all subtypes of rosacea, characterizing erythematotelangiectatic rosacea (ETR) already as a disease with signiﬁcant
inﬂux of proinﬂammatory cells. The T-cell response is dominated by Th1/Th17-polarized immune cells, as
demonstrated by signiﬁcant upregulation of IFN-γ or IL-17, for example. Chemokine expression patterns support
a Th1/Th17 polarization proﬁle of the T-cell response. Macrophages and mast cells are increased in all three
subtypes of rosacea, whereas neutrophils reach a maximum in papulopustular rosacea. Our studies also provide
evidence for the activation of plasma cells with signiﬁcant antibody production already in ETR, followed by a
crescendo pattern toward phymatous rosacea. In sum, Th1/Th17 polarized inﬂammation and macrophage
inﬁltration are an underestimated hallmark in all subtypes of rosacea. Therapies directly targeting the Th1/Th17
pathway are promising candidates in the future treatment of this skin disease.
Journal of Investigative Dermatology (2015) 135, 2198–2208; doi:10.1038/jid.2015.141; published online 14 May 2015
INTRODUCTION
Rosacea is a common, chronic inﬂammatory skin disease with
poorly understood etiology. On the basis of its symptoms such
as facial erythema, chronic inﬂammation, and ﬁbrosis (Powell,
2005), complex pathomechanisms involving dysregulation in
the immune, vascular, and nervous systems, as well as barrier
function impairments, are suggested (Yamasaki et al., 2007;
Steinhoff et al., 2011, 2013; Wollina, 2014).
The knowledge about rosacea immunology is still very
limited, and most studies focused on the involvement of the
vascular or innate immune system. Environmental rosacea
trigger factors (e.g., UV, temperature changes, spicy food,
exercise, “stress”, demodex) or an altered skin microbiome
activates (directly or indirectly) pattern recognition receptors
such as Toll-like receptors (TLRs), which stimulate the release
of antimicrobial peptides (among them the cathelicidin LL-37)
or cytokines, for example (Steinhoff et al., 2013). In rosacea,
an increased expression of TLR2, LL-37, and kallikrein 5 (the
protease that cleaves the cathelicidin precursor protein into
LL-37) has been observed (Yamasaki and Gallo, 2011; Brown
et al., 2014), and inhibition of kallikrein 5 has been linked to
improvement of the erythema and inﬂammatory papules in
rosacea (Two et al., 2014). In addition, cells of the innate
immune system, among them macrophages, mast cells, and
neutrophils, were described as part of the cellular inﬁltrate in
rosacea (Marks and Harcourt-Webster, 1969; Jansen and
Plewig, 1997; Schwab et al., 2011).
Little is known about the adaptive immune system in
rosacea. It was shown recently that in other inﬂammatory skin
diseases such as acne, psoriasis, or atopic dermatitis, the
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adaptive immune system is anticipated to contribute to the
inﬂammatory processes (Palau et al., 2013; Suarez-Farinas
et al., 2013; Kelhala et al., 2014). Only very few studies
exist, which investigate a role of the adaptive immune
system in rosacea and show that the cellular inﬁltrate in
rosacea also contains T cells and B cells (Ruﬂi and
Buchner, 1984; Aloi et al., 2000; Smith et al., 2007; Brown
et al., 2014). With regard to T cells, CD4+ T cells are reported
to be more frequently found than CD8+ T cells in
papulopustular rosacea (PPR) and in nonpustular rosacea
(Georgala et al., 2001; Brown et al., 2014). However, these
studies are only based on histological ﬁndings mainly in
pustular rosacea, and they do not investigate and distinguish
between different cutaneous rosacea subtypes simul-
taneously, and they do not correlate histological ﬁndings
with cellular pathways.
Therefore, the aim of this study was to characterize the
inﬂammatory inﬁltrate of the three cutaneous rosacea
subtypes comprehensively. Moreover, we performed whole
transcriptome expression analysis and conﬁrmed the results
with quantitative real-time reverse-transcriptase–PCR (qRT–
PCR) and quantitative immunohistochemistry of rosacea
patient samples, as compared with healthy skin and facial
lupus erythematosus (LE).
RESULTS
CD4+ T helper cells dominate the immune cell inﬁltrate in
erythematotelangiectatic rosacea (ETR) and PPR
Our study reveals strong levels of T-cell involvement in all
three rosacea subtypes (Figure 1 and Supplementary Figure S1
online), reaching a maximum of activation in PPR (PPR4phy-
matous rosacea (PhR)4ETR). At the transcriptome level,
strong upregulation of CD3G, CD3D, and CD247
(=CD3Z), which transcribe the CD3 subunits of the αβ T-cell
receptor (Wang and Reinherz, 2012), can be observed for all
rosacea stages. In addition, this correlates well with increased
expression of the T-cell activation– and proliferation–
associated genes LCK, MICB, VAV1, and LAG3 (Casati
et al., 2006; Gomez-Rodriguez et al., 2007; Cerboni et al.,
2009; Salmond et al., 2009). We also observe identical
patterns in genes encoding for costimulatory molecules for
T-cell activation (such as CD80, CD86, TNFSF14), as well as
the proinﬂammatory cytokine IL-1β (del Rio et al., 2010). For
conﬁrmation of our transcriptome data, we performed a qRT–
PCR study on a total of 68 immunological markers for each
rosacea subtype. We globally obtained a good agreement
between transcriptome and qRT–PCR results (Supplementary
Table S1 online). In support, quantitative immunohistochem-
istry (IHC) veriﬁes a signiﬁcant increase of CD4+ cells in all
subtypes, with highest CD4 counts in PPR. Interestingly,
CD4+ cells in PPR were mainly distributed around hair
follicles, whereas CD4+ cells were found to be predominantly
localized in the perivascular region in the other subtypes of
rosacea. Although expression of CD4 was only moderately
elevated in all rosacea stages (30–40% higher than controls)
based on the Affymetrix analysis, the results were always
signiﬁcant (false discovery rateo0.002 in all three stages).
Immunohistochemical staining for CD8 showed spare cells in
all three subtypes with a trend toward higher expression in
PPR, but without reaching statistical signiﬁcance. At the
transcriptome level, CD8A was signiﬁcantly elevated in all
rosacea forms (PPR4PhR4ETR), whereas the increase of
CD8B did not reach signiﬁcance.
Immune response in rosacea displays Th1/Th17 polarization
Detailed transcriptome analysis of the induced T-cell response
genes revealed signiﬁcantly higher gene expression levels for
the Th1-signature cytokines IFN-γ and tumor necrosis factor-α
(Figure 2). This ﬁnding is consistent with higher messenger
RNA expression levels for the Th1-related transcription factors
signal transducer and activator of transcription 1 and 4
(Oestreich and Weinmann, 2012). Corresponding results
were obtained for cellular receptors associated with Th1-
immune responses such as IL12RB1 and CCR5 (Turner et al.,
2007). We conﬁrmed these results by IHC and found a largely
higher staining for IFN-γ, especially in PPR.
Besides the Th1-polarized immune response in rosacea, we
also found induction of Th17-associated genes (Figure 2). The
genes coding for Th17-signature cytokines IL17A and IL22 were
signiﬁcantly elevated (again PPR4PhR4ETR). The same was
true for the genes IL6, tumor necrosis factor, IL20, and CCL20,
which induce IL-17/IL-22 production, and for the Th17-
associated transcription factor signal transducer and activator
of transcription 3 (Lyakh et al., 2008; Rutz et al., 2013). These
results were veriﬁed by signiﬁcant IL-17 immunostaining in all
subtypes, with highest staining in PPR patients. Neither
transcriptome nor IHC analysis veriﬁed an involvement of
Th2-associated genes of the cytokine IL-4 (Supplementary
Figure S2 and S3 online). Finally, no upregulation of genes
were found associated with activation of regulatory T cells
(unaltered expression of FOXP3, IL10, CCR4, and CCR8,
depicted in Supplementary Figure S3 online).
Recruitment and activation of macrophages and neutrophils
differ between rosacea subtypes
To deﬁne an involvement of macrophages in rosacea, we
analyzed messenger RNA expression levels of CD68, CD14,
CD163, and MSR1. The ﬁnding of signiﬁcant upregulation of
these macrophage markers in PPR was supported by identical
upregulation of ITGB2 and ITGAM messenger RNA (Figure 3),
genes that encode proteins that form the macrophage-1
antigen (or integrin αMβ2). Several other important activators
of macrophages (and other inﬂammatory immune cells) were
also signiﬁcantly upregulated at the transcriptome level, once
more following the pattern PPR4PhR4ETR: TLR1, TLR4,
CHI3L1/YKL-40, ARG1 (Rathcke and Vestergaard, 2006;
Gordon and Martinez, 2010; Gallego et al., 2011).
Immunohistochemical staining for CD68 conﬁrmed our
transcriptome data, demonstrating highly signiﬁcant
increases of CD68+ cells in all subtypes (PPR: Po0.001,
ETR and PhR: Po0.05). In particular in PPR, CD68+ cells
were vastly organized as granulomatous areas and
interfollicularly (Figure 3), whereas ETR macrophages showed
a more perivascular diffuse pattern similar to CD4+ cells.
Next, we analyzed RNA levels and distribution of
neutrophils in all three subtypes of rosacea. Transcriptome
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Figure 1. Rosacea shows activation and proliferation of T cells, which is mainly owing to CD4+ T helper cells, but not CD8+ cytotoxic T cells. The table (a)
depicts genes that are involved in T-cell activation and proliferation and signiﬁcantly modulated in at least one of the rosacea subtypes (full list of gene sets in
Supplementary Figure S1 online). Fold modulations in bold face type depict false discovery rate (FDR)o0.05; fold modulations in italic type depict FDR40.05.
The upper graphs depict representative pictures (b,c,e–g) and morphometric analysis (d) of CD4+ cells in each rosacea subgroup (erythematotelangiectatic
rosacea/rosacea type I (RI), papulopustular rosacea/rosacea type II (RII), phymatous rosacea/rosacea type III (RIII)), lupus erythematosus (LE) patients, and healthy
skin (HS), all comprising n≥ 5 patients with ﬁve representative areas per slide (eff.pos.area = effective positive area). The lower graphs and pictures display the
results for CD8+ cells (h–m). All images are × 200 magniﬁcation (bar=100 μm).
Figure 2. The T helper cell subset is polarized toward a Th1/Th17 immune response. The upper table (a) shows Th1 cell–related genes signiﬁcantly modulated
in at least one of the rosacea subtypes. Fold modulations in bold face type depict false discovery rate (FDR)o0.05; fold modulations in italic type depict
FDR40.05. Representative pictures of IFN-γ staining by immunohistochemistry (IHC) are depicted below (b–g), with results shown in each rosacea subgroup
(erythematotelangiectatic rosacea/ rosacea type I (RI), papulopustular rosacea/rosacea type II (RII), phymatous rosacea/rosacea type III (RIII)), healthy skin (HS),
murine spleen, and controls without primary antibody. The lower table (h) displays signiﬁcant alterations of Th17 cell–related gene expression only and
corresponding IHC for IL-17A (i–n). All images are × 200 magniﬁcation (bar=100 μm); inserts taken from the same slide located in the lower right corner are
×1,000 magniﬁcation (bar=20 μm). More detailed gene lists including nonaltered Th2 and regulatory T-cell gene sets, as well as IHC for noninvolved IL-4 in
rosacea, are displayed in Supplementary Figure S2 and S3 online.
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analysis of CXC chemokines (Figure 3) shows signiﬁcant
upregulation of CXCL8 messenger RNA (formerly known
as IL-8 or neutrophil chemotactic factor), one of the most
potent chemotactic molecules for neutrophils. Similarly,
other chemotactic chemokines such as CXCL1, CXCL2,
CXCL5, and CXCL6 were found to be upregulated (Scapini
et al., 2000). Although neutrophils were found in pustular
regions of PPR and PhR patients by immunohistochemistry,
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we found no evidence for an involvement of neutrophils
in ETR.
Using immunohistochemistry (CD1a) and transcriptome
analysis, no signiﬁcant cell enhancement or RNA upregula-
tion was observed for Langerhans cells in all three rosacea
subtypes (Supplementary Figure S5 online). Distribution and
transcriptome analysis of mast cells has recently been
published (Schwab et al., 2011).
Involvement of B cells and plasma cells in the regulation of
immune responses in rosacea
Transcriptome analysis revealed signiﬁcantly increased RNA
expression levels of the B-cell marker MS4A1 (CD20) in PPR
and PhR (Figure 4, Supplementary Figure S6 online). Similar
results were obtained for the PAX5 gene, which encodes the
transcription factor B-cell lineage–speciﬁc activator protein,
and for the expression of CD24, which functions on activated
B cells as a T-cell costimulator for CD4+ T-cell clonal
expansion (Fang et al., 2010; Medvedovic et al., 2011). We
also found up to 170-fold upregulated genes involved in
different parts of the light and heavy chains for immunoglo-
bulins. Interestingly, all these genes reached the highest
expressions in PhR (Figure 4). Because rearrangement and
combinatorial procedures of immunoglobulins are especially
complex in molecule assembly, these results need to be
evaluated carefully. With IHC, we found highly signiﬁcant
increases in CD79a+ cells in all rosacea subtypes, with
highest cell numbers in PhR. Of note, CD79a+ cells were
often localized perivascularly or perifollicularly, or grouped
as pseudofollicles in the papillar dermis. CD20 immunostain-
ing showed an identical increase of positive cells in ETR and
PPR, but dropped to almost baseline expression in PhR. As
CD79a positivity is retained in plasma cells, whereas this late
stage of B-cell differentiation shows no CD20 expression, it
may be concluded that most of the CD79a+ cells in PhR are in
fact immunoglobulin-producing plasma cells (Chu and Arber,
2001). Analysis of several genes roughly differentiating
antigen-dependent (e.g., CD28) and antigen-independent
(e.g., IL6, IL7) B-cell activation did not show a distinct pattern
of activation (Figure 4).
Chemokine expression patterns support the Th1/Th17
polarization of the T-cell response
As the family of chemokines appears redundant and their
ligand–receptor relationships are promiscuous for many cell
types, interpretation of immune cell and immune system
polarization behavior by chemokines needs to be done with
caution (Zlotnik and Yoshie, 2012). Moreover, as ligands of
the Th1 cell–associated receptor CXCR3 and the Th2 cell–
associated CCR3 are reciprocally natural antagonists, these
ligands can form mutually exclusive microenvironments that
are in favor of either Th1 or Th2 cell differentiation (Loetscher
et al., 2001). Among all chemokines, we found the highest
expression levels for the CXCR3 ligands CXCL9, CXCL10,
CXCL11, and CXCL13 (which are also induced by IFN-γ). In
contrast, CCR3 ligands such as CCL3, CCL5, CCL11, and
CCL13 were only modestly upregulated or unchanged
compared with healthy controls (Figure 5).
The also highly expressed CCL18 acts as an antagonist to
CCR3 (Nibbs et al., 2000). Th17 cells express CCR6, which is
only known to be activated by the highly elevated CCL20
and by β-defensin-2 (Singh et al., 2008). Activation of
macrophages and neutrophil granulocytes is also reﬂected
by the increased expression proﬁle of the receptors CCR1,
CCR2, CCR5, CCR7 (macrophages and monocytes), and
CXCR2 (neutrophils), and their corresponding ligands CCL2,
CCL3, CCL4, CCL5, CCL8, CCL19, and CXCL1, CXCL2,
CXCL5, CXCL6, respectively (Gerber et al., 2011). In contrast,
CCL27 and IL-37 are the most signiﬁcantly downregulated
transcripts among all cytokines and chemokines, emphasizing
again the importance of Th1/Th17 involvement in the
pathophysiology of rosacea. CCL27 is involved in cutaneous
homing of Th2 cells in atopic dermatitis, it is downregulated
in psoriasis plaques, and IFN-γ has been demonstrated to be
the responsible component for downregulation of CCL27 in
keratinocytes (Nomura et al., 2003; Riis et al., 2011). IL-37
(IL-1F7) suppresses immune responses, and its protective
activity affects a broad spectrum of Th1/Th17 proinﬂamma-
tory insults, placing this cytokine as a new member in the
portfolio of anti-inﬂammatory cytokines such as IL-10 or TGF-
β (Nold et al., 2010). Thus, the considerable downregulation
of the anti-inﬂammatory IL-37 may result in increased
inﬂammation in rosacea. In summary, although a vast
majority of altered cytokines and chemokines reach their
maximum of upregulation and downregulation in PPR
patients, signiﬁcant changes in the RNA expression levels
for cytokines/chemokines can be observed in all three
cutaneous subtypes.
DISCUSSION
Although of importance, a detailed characterization of the
inﬂammatory inﬁltrate and the associated cytokine/chemo-
kine proﬁles in the three skin subtypes of rosacea has not been
performed yet. Here, we comprehensively analyzed the
inﬂammatory inﬁltrate of the three rosacea subtypes (ETR,
PPR, and PhR) in comparison with healthy skin. In addition,
we characterized the inﬂammation hallmarks of rosacea and
LE, a facial chronic inﬂammatory autoimmune disease of
different origin. Our combined transcriptome and immuno-
histochemistry analysis demonstrates Th1/Th17 dominance in
all three subtypes (Figures 1 and 2), as well as the presence of
macrophages (Figure 3) and mast cells in all subtypes
(Schwab et al., 2011). In contrast, B cells or neutrophils
can only be found in PPR and PhR with a speciﬁc staining
pattern. In contrast, activation of Langerhans cell–associated
genes or cell numbers could not be observed. Together,
these observations suggest the involvement of the innate
and adaptive immune system in the pathophysiology of
rosacea.
Recently, the involvements of a dysfunctional innate
immune system and a dysregulated neuro-immune commu-
nication network controlling vascular responses have been
discovered as important contributors in the pathophysiology
of rosacea. In early rosacea (ETR), a malicious vasodilation to
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normally innocuous physical stimuli (sunlight, temperature
changes, spices) and associated imbalanced neuro-immune
circuits may be important for the characteristic ﬂushing
responses of rosacea patients (Schwab et al., 2011; Steinhoff
et al., 2011; Sulk et al., 2012). A detailed analysis of the
inﬂammatory mediators and cells that are involved in innate
and adaptive immunity in rosacea patients, however, is so far
lacking.
We show that the adaptive immune system is broadly and
signiﬁcantly activated, which interestingly starts as early as in
ETR, and increases further in PPR. We identiﬁed the increased
T-cell population as consisting of predominantly CD4+ T
helper cells, and our transcriptome data revealed an
upregulation of Th1- and Th17-polarizing gene sets. We
conﬁrmed these ﬁndings by immunohistochemistry for the
signature cytokines IFN-γ and IL-17A. Of note, the highest
increase for all genes involved was observed in PPR, followed
by PhR and ETR (both with roughly comparable changes). We
observed an identical pattern of activation in macrophages
and neutrophils (PPR4PhR4ETR). Together with our data
that mast cells and mast cell–associated genes are increased
in all three subtypes of rosacea, our studies indicate a critical
role of Th1/Th17 and mast cells, as well as for macrophages in
rosacea pathophysiology.
Previous studies on T cells in rosacea have been very
limited in number or subtypes, and were exclusively histology
based. One recent study compared T-cell subsets in
nonpustular rosacea vs. LE patients with immunohistochem-
istry (Brown et al., 2014). They found a T cell–rich
lymphocytic inﬁltrate in rosacea with a ratio of CD4+/CD8+
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Figure 3. Recruitment and activation of macrophages and neutrophils differ between rosacea stages. The upper table (a) depicts monocyte/macrophage-related
genes signiﬁcantly modulated in at least one of the rosacea subtypes, which are involved in activation and proliferation (full list of gene sets in Supplementary
Figure S4 online). Fold modulations in bold face type depict false discovery rate (FDR)o0.05; fold modulations in italic type depict FDR40.05. The graphs depict
representative pictures (b,c,e–g) and morphometric analysis (d) of CD68+ cells in each rosacea subgroup (erythematotelangiectatic rosacea/rosacea type I (RI),
papulopustular rosacea/rosacea type II (RII), phymatous rosacea/rosacea type II (RIII)), lupus erythematosus (LE) patients, and healthy skin (HS), all comprising
n≥ 5 patients with ﬁve representative areas per slide (eff.pos.area = effective positive area). The lower table (h) displays neutrophil-associated genes with
signiﬁcant modulation.
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T cells of 2.80. This is in line with our detailed ﬁndings of
a CD4+ T cell–driven inﬂammatory response and their
associated genes. Two other histological studies also
describe an increase of CD4+ over CD8+ cells exclusively
in PPR patients, and in ocular rosacea, respectively (Hoang-
Xuan et al., 1990; Georgala et al., 2001). Our study, however,
suggests a contribution of CD4+ cells already in ETR, and also
in PhR, although at different levels. In support, CD4+
-associated genes are already signiﬁcantly upregulated in ETR.
Of note, Th17 pathways were recently unveiled as being
importantly involved in acne vulgaris (Agak et al., 2014). In
one transcriptome study on acne patients, the pattern of
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upregulated genes was widely comparable to the pattern that
we observed in rosacea (Kelhala et al., 2014). Kistowska et al.
(2015) have demonstrated that Propionibacterium acnes has a
central role in driving the Th17/Th1 response in acne vulagris.
Hypothetically, microorganisms may also be involved in
polarizing the Th1/Th17 immune response in rosacea,
although the role of microorganisms has been a matter of
considerable debate in recent years. Several studies link the
microbes Demodex folliculorum, Bacillus oleronius,
Helicobacter pylori, Staphylococcus epidermidis, Chlamydia
pneumoniae, and Bartonella quintana to rosacea
pathophysiology (Holmes, 2013; Murillo et al., 2014).
Underlying mechanisms may be increased by bacterial
loads and/or hyperreactivity of the patients’ immune
system. Nevertheless, the causative role of microorganisms
(and especially Demodex spp. and/ or their associated
microbiota) remains unclear in rosacea as of now. Although
reduction of facial Demodex colonization has been
achieved in multiple clinical trials on rosacea, a higher
reduction of Demodex colonization did not directly translate
into better clinical outcome in these patients (Kocak et al.,
2002).
It has been well recognized over the past years that
dysregulation of the innate immune response contributes to
rosacea pathophysiology signiﬁcantly. The antimicrobial pro-
protein cathelicidin and its fragment LL-37 were found to be
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elevated and abnormally processed (Yamasaki et al., 2007),
and pattern-recognition receptors (TLR2, NALP3) were
upregulated (Yamasaki et al., 2011; Casas et al., 2012). As
the kallikrein (KLK) serine proteases 5 and 7 are major
activators of antimicrobial peptides such as cathelicidin, the
abundance of KLK5 in rosacea is responsible for processing
the excess cathelicidins into aberrant forms, which fuels the
course of the disease (Yamasaki et al., 2007). Interestingly, it
was recently shown that IL-17 can also contribute to the
induction of LL-37 expression levels in keratinocytes (Chen
et al., 2013; Sakabe et al., 2014), and therefore Th17
cytokines may also lead to or enhance the dysregulation of
LL-37 expression.
Besides polarization of Th1/Th17-dominated immune
responses, we also demonstrated upregulation of macro-
phage- and neutrophil-associated gene sets, as well as the
inﬂux of macrophages and their perifollicular and perivas-
cular localization by IHC. This adds up well to our recently
published observations on upregulation of mast cells in all
rosacea subtypes, reaching a maximum in PPR (Schwab et al.,
2011). We did not observe any signiﬁcant activation or
expansion of Langerhans cells by transcriptome data,
quantitative PCR, and IHC in all rosacea substages.
With regard to B cells, we found an unexpectedly massive
upregulation of immunoglobulin-associated gene sets in all
subgroup analyses, and IHC conﬁrmed a signiﬁcant increase
in plasma cells, but not of CD20+ B cells (Figure 4). Plasma
cells and antibody production showed the highest involve-
ment in PhR at the gene level, and strikingly already ETR
patients revealed a signiﬁcant increase in plasma cell
numbers. Although the increase of plasma cells has been
acknowledged in earlier studies, only limited research has
focused on their pathophysiological role in rosacea (Smith
et al., 2007; Cribier, 2013). Thus, the role of plasma cells in
rosacea pathophysiology remains highly speculative at this
time. Interestingly, the bacterium B. oleronius can be isolated
from a D. folliculorum mite extracted from a PPR patient
(Lacey et al., 2007). It was demonstrated that two highly
immunogenic proteins from B. oleronius were capable of
mounting an inﬂammatory response in PPR patients. Of note,
the same reactivity to B. oleronius was already found in ETR
patients, and also conﬁrmed in patients with ocular rosacea
(O'Reilly et al., 2012; Jarmuda et al., 2014). These promising
ﬁndings warrant further veriﬁcation, and proof of clinical
improvement in patients with decreased numbers of B.
oleronius is still lacking. Alternatively, autoimmune
processes associated with molecular mimicry of antigens
from microbiota and skin cells cannot be excluded, and
should be more considered in the future.
In conclusion, our study showed signiﬁcant involvement of
the immune system in all subtypes of rosacea, characterizing
even ETR as a chronic disease with signiﬁcant inﬂammatory
activity. The T-cell response is dominated by a Th1/Th17-
polarized immune response, as we veriﬁed by correlating
enhanced expression proﬁles and staining for signature
cytokines including IFN-γ and IL-17. Chemokine expression
patterns also support the Th1/Th17 polarization of the T-cell
response, and recruitment, as well as activation, of macro-
phages or neutrophils, which is already present in ETR and
reaches a maximum in PPR. Our current hypothesis of the
complex interplay of the different skin cells in rosacea is
depicted in Figure 6. We also provide evidence for
a vast activation of antibody-producing plasma cells,
beginning already in ETR, followed by a crescendo pattern
toward PhR. Thus, an altered adaptive, as well as innate,
immunity is the hallmark in the development of rosacea.
Therapies targeting the Th1/Th17 pathway are promising
candidates for an optimized treatment of this frequent,
chronic skin disease.
MATERIALS AND METHODS
Tissue collection and patients selection
For Affymetrix microarray studies and qRT–PCR-analysis, we studied
a group of 19 rosacea patients, of whom 7 were diagnosed with ETR,
6 with PPR, and 6 with PhR based on the classiﬁcation system of the
American Rosacea Society (Wilkin et al., 2002). Skin biopsies were
taken for all disease subtypes from the nasolabial fold of the patients
with the aim to minimize differences based on biopsy localization. In
addition, skin biopsies of 10 healthy individuals were investigated.
Patients with systemic LE displaying a malar rash were identically
biopsied from the nasolabial fold for comparison. Skin biopsies were
obtained in local anesthesia after the patients gave their written
consent. Permission for human studies was given by the Ethical
Committee of the University of Münster, Germany, in accordance
with the ethical standards of the 1964 Declaration of Helsinki
Principles.
Supplement material
Additional materials and methods for this manuscript can be found in
the supplement.
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